R
Radka Obermannova
Researcher at Masaryk University
Publications - 59
Citations - 2505
Radka Obermannova is an academic researcher from Masaryk University. The author has contributed to research in topics: Cancer & Ramucirumab. The author has an hindex of 13, co-authored 44 publications receiving 1789 citations. Previous affiliations of Radka Obermannova include European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: In the EU, the highest age-standardised incidence rates for oesophageal cancer are in the Netherlands for men and the UK for women, and variation between countries is high and may reflect different prevalence of risk factors, use of screening and diagnostic methods.
Journal ArticleDOI
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,György Bodoky,Rocio Garcia-Carbonero,Tudor Ciuleanu,David Craig Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García-Alfonso,Kentaro Yamazaki,Philip Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao Chun Chang,F. Nasroulah +18 more
TL;DR: Ramucirumab plus F OLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma and toxic effects were manageable.
Journal ArticleDOI
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
Bohuslav Melichar,Antoine Adenis,A. Craig Lockhart,Jaafar Bennouna,E. Claire Dees,Omar Kayaleh,Radka Obermannova,Angela DeMichele,Petr Zatloukal,Bin Zhang,Claudio Dansky Ullmann,Claudia Schusterbauer +11 more
TL;DR: These data support further clinical assessment of alisertib in patients with solid tumours, particularly those with breast cancer and small-cell lung cancer.
Journal ArticleDOI
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Charles S. Fuchs,Kohei Shitara,Maria Di Bartolomeo,Sara Lonardi,Salah-Eddin Al-Batran,Eric Van Cutsem,David H. Ilson,Maria Alsina,Ian Chau,Jill Lacy,Michel Ducreux,Michel Ducreux,Guillermo Mendez,Alejandro Molina Alavez,Daisuke Takahari,Wasat Mansoor,Peter C. Enzinger,Vera Gorbounova,Zev A. Wainberg,Susanna Hegewisch-Becker,David Ferry,Ji Lin,Roberto Carlesi,Mayukh Das,Manish A. Shah,Manish A. Shah,Alexander Luft,Nina A. Karaseva,Rubén Dario Kowalyszyn,Carlos Alberto Hernandez,Tibor Csoszi,Ferdinando De Vita,Per Pfeiffer,Naotoshi Sugimoto,Judit Kocsis,Andràs Csilla,György Bodoky,Georgina Garnica Jaliffe,Svetlana Protsenko,A Madi,Elzbieta Wojcik,Baruch Brenner,Gunnar Folprecht,Tomasz Sarosiek,Katriina Peltola,Peter Bono,Hubert Ayala,Giuseppe Aprile,Cardellino Giovanni Gerardo,Fidel David Huitzil Melendez,Alfredo Falcone,Francesco Di Costanzo,Moustapha Tehfe,Laurent Mineur,Pilar Garcia Alfonso,Radka Obermannova,Hélène Senellart,Russell D. Petty,Leslie Samuel,Peter Istvan Acs,Maen A. Hussein,Marina N. Nechaeva,F.L.G. Erdkamp,Elizabeth Won,Johanna C. Bendell,Javier Gallego Plazas,Sylvie Lorenzen,Bohuslav Melichar,Miguel Angel Escudero,Denis Pezet,Jean-Marc Phelip,Diego Lucas Kaen,James A. Jr Reeves,Federico Longo Munoz,Srinivasan Madhusudan,Carlo Barone,Luis Fein,Angel Gomez Villanueva,Mohamed Hebbar,Jana Prausová,Laura Visa Turmo,Joana Vidal Barrull,Mette Karen Yilmaz,Alex Beny,H.M.W. Van Laarhoven,Brian Anthony DiCarlo,Taito Esaki,Kazumasa Fujitani,Karen Geboes,Ravit Geva,Shigenori Kadowaki,Stephen Leong,Nozomu Machida,Moses Sundar Raj,Francisco Javier Ramirez Godinez,Agnes Ruzsa,Hugo Ford,William E. Lawler,Nicolas Robert Maisey,Jiri Petera,Einat Shacham-Shmueli,Isabelle Sinapi,Kensei Yamaguchi,Hiroki Hara,J.T. Beck,Maria Błasińska-Morawiec,Ricardo Villalobos Valencia,Thierry Alcindor,Madhuri Bajaj,Scott M. Berry,Christina Maria Gomez,Daniel Dammrich,Ravindranath Patel,Julien Taieb,A.J. Ten Tije,Ronald L. Burkes,Fernando Cabanillas,Irfan Firdaus,Cynthia Coo Chua,Shuichi Hironaka,Ralf-Dieter Hofheinz,Howard J. Lim,Marianne Nordsmark,Bela Piko,Udit Verma,Jonathan Wadsley,Seigo Yukisawa,Francisco Gutiérrez Delgado,Crystal S. Denlinger,Raija Kallio,Joanna Pikiel,Joanna Wojcik-Tomaszewska,Christine Brezden-Masley,Raymond Jang,Jana Pribylova,Daisuke Sakai,Maria Alejandra Bartoli,Annemieke Cats,M.I. Grootscholten,Robert Andrew Dichmann,Hugo Hool,Walid Shaib,Akihito Tsuji,Marc Van den Eynde,Hector Velez-Cortez,Timothy R. Asmis +145 more
TL;DR: The addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Journal ArticleDOI
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Josep Tabernero,Josep Tabernero,Rebecca R. Hozak,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,G. Bodoky,Rocio Garcia-Carbonero,Tudor-Eliade Ciuleanu,David Craig Portnoy,Jana Prausová,K. Muro,Robert W. Siegel,Robert J. Konrad,H. Ouyang,Symantha Melemed,David Ferry,F. Nasroulah,E. Van Cutsem +18 more
TL;DR: The RAISE biomarker program identified VEGF-D as a potential predictive biomarker for ramucirumab efficacy in second-line mCRC and identified an assay appropriate for testing in clinical practice is currently ongoing.